AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Non-interventional Study to Investigate the Current Situation of Asthma-COPD Overlap Syndrome in Patients Over Age 40 With Persistent Airflow Limitation in China
Completed
- Conditions
- Asthma-COPD Overlap Syndrome
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2016
- Registration Number
- NCT02600221
- Locations
- 🇨🇳
Research Site, Hangzhou, Zhejiang, China
Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients
Completed
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1200
- Registration Number
- NCT02588859
- Locations
- 🇮🇳
Research Site, new Delhi, India
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
Phase 1
Completed
- Conditions
- MelanomaLung CancerBreast CancerPancreatic AdenocarcinomaBiliary Tract CancerHead and Neck CarcinomaGastroesophageal CancerColorectal Cancer
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 58
- Registration Number
- NCT02586987
- Locations
- 🇺🇸
Research Site, Pittsburgh, Pennsylvania, United States
Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer
Phase 1
Completed
- Conditions
- Advanced Solid Tumours
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 84
- Registration Number
- NCT02588105
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
Phase 1
Completed
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Drug: MEDI4736 in combination with AZD5069
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 23
- Registration Number
- NCT02583477
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM
Phase 3
Completed
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 151
- Registration Number
- NCT02582814
- Locations
- 🇯🇵
Research Site, Yokohama-shi, Japan
The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM
Phase 1
Completed
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT02582840
Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore
Completed
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 201
- Registration Number
- NCT02578563
- Locations
- 🇸🇬
Research Site, Singapore, Singapore
A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT02579226
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease
Phase 2
Terminated
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 29
- Registration Number
- NCT02574637
- Locations
- 🇪🇸
Research Site, L'Hospitalet de Llobregat, Spain
🇺🇸Ehrhardt Clinical Research, LLC, Belton, Missouri, United States
🇺🇸Premier Medical Group of the Hudson Valley, PC, Poughkeepsie, New York, United States